12:41:06 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Q:MRNA - MODERNA INC - https://www.modernatx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRNA - Q2.5204.15·204.571.5204.325-2.475-1.23,139.8628,83643,080206.80  208.68  199.20280.80  22.2912:23:02Nov 1215 min RT 2¢

Recent Trades - Last 10 of 43080
Time ETExPriceChangeVolume
12:23:09Q204.51-2.292
12:23:08Q204.57-2.231
12:23:08Q204.4241-2.37591
12:23:07Q204.37-2.433
12:23:06Q204.33-2.4750
12:23:04Q204.17-2.634
12:23:04Q204.57-2.232
12:23:03Q204.325-2.4751
12:23:02Q204.2188-2.58121
12:23:02Q204.37-2.431

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-12 07:00U:MRNANews ReleaseModerna Outlines Next Phase of Growth at Analyst Day
2026-11-11 11:11U:MRNANews ReleaseModerna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
2026-11-10 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conference in November 2026
2026-11-06 06:45U:MRNANews ReleaseModerna Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-05 17:21U:MRNANews ReleaseHealth Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
2026-11-04 11:05U:MRNANews ReleaseModerna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
2026-11-04 09:55U:MRNANews ReleaseModerna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
2026-10-26 09:00U:MRNANews ReleaseImmuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
2026-10-26 08:53U:MRNANews ReleaseA Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
2026-10-23 07:00U:MRNANews ReleaseModerna Named a Top Employer by Science for Twelfth Consecutive Year
2026-10-22 14:59U:MRNANews ReleaseMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA(TM) (pembrolizumab) at ESMO 2026 Presidential Symposium
2026-10-14 09:45U:MRNANews ReleaseAI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
2026-10-13 07:00U:MRNANews ReleaseModerna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
2026-09-30 07:00U:MRNANews ReleaseModerna Adds Chief Operating Officer Role as Company Expands into Oncology
2026-09-21 10:12U:MRNANews ReleaseModerna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
2026-09-15 09:00U:MRNANews ReleaseA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
2026-09-01 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conferences in September 2026
2026-08-28 07:00U:MRNANews ReleaseModerna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
2026-08-27 15:57U:MRNANews ReleaseModerna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
2026-08-27 07:21U:MRNANews ReleaseModerna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes